Loading...
Explore Q-Line Biotec SME IPO details, including IPO dates, financial statements, valuation, peer comparison and more.
Q-Line Biotech Ltd., incorporated in 2010, is a company focused on the development, manufacturing, and marketing of a diverse range of diagnostic healthcare products. Their core business involves reagents, including kits and Point-of-Care (POC) devices, as well as consumables. Additionally, Q-Line Biotech manufactures, imports, distributes, and supplies diagnostic equipment.
The company primarily serves diagnostic service providers, hospitals, and medical colleges. Their key manufacturing segments encompass indigenous production of reagents for Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics, and Other categories like POC Devices & Rapids, alongside manufacturing and supplying in-vitro diagnostics (IVD) and pathology equipment.
Key highlights of Q-Line Biotech include:
Discover essential information crucial for understanding an IPO, including the Price Band, Fresh Issue, Offer For Sale, Total IPO Size and more. Explore these key details to gain insight into the company's public offering.
| Fields | Details |
|---|---|
| IPO Dates | 21 May - 25 May 2026 |
| IPO Price Band | ₹326 - ₹343 per share |
| Fresh Issue | ₹203.74 crore |
| Offer For Sale | NIL |
| Total IPO Size | ₹214.48 crore |
| Face Value | ₹10 |
| Listing On | NSE SME |
Explore important dates like IPO opening, closing, listing and others, outlining the journey of the Public Offering. This will help you grasp the entire IPO journey effortlessly.
| Event | Date |
|---|---|
| IPO Opening Date | 21 May 2026 |
| IPO Closing Date | 25 May 2026 |
| Basis Of Allotment | 26 May 2026 |
| Refunds | 27 May 2026 |
| Demat Transfer | 27 May 2026 |
| IPO Listing Date | 29 May 2026 |
Explore a comprehensive financial data table showcasing key metrics including revenue, expenses, net income, and others. Gain valuable insights about the company's financial performance at a glance, facilitating informed decision-making and strategic planning for subscribing to the IPO.
| Period Ended | 31 Mar 2023 | 31 Mar 2024 | 31 Mar 2025 | 31 Dec 2025 |
|---|---|---|---|---|
| Assets | 251.58 | 339.25 | 455.49 | 561.34 |
| Total Income | 184.81 | 206.45 | 322.58 | 236.50 |
| Profit After Tax | 32.10 | 34.44 | 28.13 | 38.69 |
| EBITDA | 32.98 | 37.63 | 71.32 | 64.23 |
| NET Worth | 127.37 | 161.81 | 189.95 | -0.04 |
| Reserves and Surplus | 125.79 | 160.24 | 188.37 | 2,12,88,920.00 |
| Total Borrowing | 73.65 | 96.91 | 164.95 | 243.85 |
* NPM represents the net profit margin, calculated as a percentage. All other figures are presented in crore (₹cr)
Compare key financial metrics with industry peers to gain valuable insights into the company's performance compared to its competitors.
| Name | P/E | EPS | RoNW | NAV |
|---|
* Revenue in (₹cr), RoNW in (%), EPS, NAV in (₹). P/E ratio is based on the highest price from the IPO price band.
| Investor Type | Shares Offered |
|---|---|
| Qualified Institutional Buyer (QIB) | 29,69,200 |
| Non-Institutional Investor (NII/HNI) | 8,91,600 |
| Retail Individual Investor (RII) | 20,79,200 |
As the issue has not yet opened, subscription data is unavailable. However, you can view subscriptions for other ongoing issues here.
Purva Sharegistry (India) Private Limited
Phone: +91 022 4961 4132/3190 8810
Email: newissue@purvashare.com
Website: www.purvashare.com
Q-Line Biotech Ltd.298-281,
Transport Nagar,
Kanpur Road Adjacent Transport Nagar Metro Station
Lucknow, – 226012https://qlinebiotech.com/+91 522-2435570compliance@qlinebiotech.com